Supreme Court Dismisses Challenge to India's Nationwide HPV Vaccination Campaign

The Supreme Court of India on September 10, 2026, refused to entertain a Public Interest Litigation that raised concerns over the central government's nationwide human papillomavirus vaccination campaign. The public health initiative, which targets adolescent girls to prevent cervical cancer, was defended by the top court as a critical measure for the health of millions of children. A three-judge bench headed by Chief Justice of India Surya Kant declined to hear the petition, prompting the petitioner's counsel to withdraw the plea.

The legal challenge arrived at a time when the central government is actively rolling out its immunisation drive across various states. The program, which utilizes a single-dose quadrivalent vaccine, represents one of the largest public health interventions aimed at reducing the burden of cervical cancer in India. By dismissing the challenge, the apex court cleared a major legal hurdle for the ongoing campaign, signaling strong judicial reluctance to interfere with established national immunization policies.

During the hearing, the bench, which also included Justices Joymalya Bagchi and V. Mohana, expressed strong reservations regarding the intent behind the petition. The judges orally observed that the Public Interest Litigation was filed with an ulterior motive and lacked bonafide. The court warned the petitioner against forcing the bench to record severe formal criticisms of the organization's actions, particularly given the medical background of its members.

Addressing the petitioner's counsel, the bench observed: "Would you like to withdraw? Do you want us to comment something?" The judges further emphasized the gravity of the matter, stating: "Don't ask us to make harsh observations. If petitioner members are doctors, it's a very very serious issue. It's a question of health of millions of our daughters. And you want to derail this." The bench made it clear that any isolated instances of medical negligence or incorrect administration would be handled through existing legal channels, noting that whenever there is a case of incorrect vaccination, ordinary rules of compensation will apply.

The petition was filed by the Universal Health Organisation, an entity that challenged the specific administrative framework under which the government-backed human papillomavirus vaccination programme is being executed. In its legal filings, the organization alleged that the current implementation strategy violates fundamental constitutional guarantees. Specifically, the plea argued that the campaign fails to uphold principles of informed consent, bodily autonomy, transparency, and administrative accountability.

Defending the petition against the court's sharp remarks, the appearing counsel argued that the litigation was not intended to promote vaccine hesitancy. The lawyer stated: "I am not at all anti-vaccine. My first contention is the way it is being implemented. Second, there is no adverse event mechanism. Whenever there is an adverse event, it must be monitored. There should also be a compensation scheme." Despite these assertions, the counsel chose to withdraw the petition entirely after the bench made its disinclination to entertain the matter clear, resulting in the case being dismissed as withdrawn.

The nationwide human papillomavirus vaccination campaign was officially launched by Prime Minister Narendra Modi on February 28 from Ajmer in Rajasthan. Designed as a targeted preventive health intervention, the campaign specifically focuses on 14-year-old girls across the country. The initiative seeks to address cervical cancer, which remains one of the leading causes of cancer-related mortality among women in India, by administering the vaccine at an age before exposure to the virus typically occurs.

The government's strategy relies on a systematic rollout through schools and community health centers to maximize coverage. By targeting adolescent girls at a specific age cohort, public health administrators aim to build herd immunity and drastically lower the long-term incidence of cervical malignancies. The program has been positioned as a cornerstone of India's preventive healthcare strategy, receiving substantial administrative backing and resources from the union health ministry.

The campaign utilizes the Gardasil 4 vaccine, a quadrivalent human papillomavirus vaccine administered in a single-dose regimen. This specific vaccine formulation is designed to provide strong protection against four distinct types of the virus, namely types 6, 11, 16, and 18. Among these, HPV types 16 and 18 are well-documented as the primary oncogenic strains responsible for the vast majority of cervical cancer cases globally, while types 6 and 11 are associated with other benign conditions.

Medical literature and global health guidelines support the efficacy of quadrivalent vaccines in preventing persistent infections that can progress to cellular abnormalities and invasive cancer. The transition to a single-dose schedule under the Indian national campaign reflects recent global clinical consensus, which suggests that a single dose offers comparable protective efficacy to multi-dose regimens for adolescent cohorts. This single-dose approach also simplifies logistics, reduces procurement costs, and improves overall compliance rates across diverse socio-economic regions.

With the Supreme Court dismissing the challenge, the union government is expected to proceed with the vaccination campaign without further judicial interruption. The court's clarification that ordinary rules of compensation will apply to any cases of incorrect vaccination establishes a clear legal pathway for individual grievances without halting the broader public health initiative. This distinction separates systemic policy challenges from individual medical negligence claims, ensuring that the national program remains protected from wholesale litigation.

Public health authorities are continuing to monitor the rollout across various states, focusing on cold-chain logistics and training healthcare workers to ensure safe administration. While the petitioner's concerns regarding adverse event monitoring and compensation schemes were not addressed through a formal judicial order, the withdrawal of the PIL leaves the responsibility of safety monitoring entirely with the Ministry of Health and Family Welfare. The ministry maintains its standard adverse events following immunization tracking systems to record and investigate any post-vaccination complications.